Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions.

Human atheromata obtained in vivo were used to test the hypothesis that transforming growth factor-beta 1 plays a role in the development of vascular restenosis. We analyzed 28 specimens from patients with primary atherosclerotic or restenotic lesions; 26 of these were obtained by directional atherectomy and 2 at the time of coronary bypass surgery. Seven control tissues included operatively excised segments of human internal mammary artery, myocardium, and unused portions of vein graft obtained intraoperatively. From these 35 specimens, 210 sections were examined using in situ hybridization. Measurement of silver grains/nucleus disclosed that expression of transforming growth factor-beta 1 mRNA was highest in restenotic tissues (P < 0.001 vs. primary atherosclerotic tissues) and lowest in nonatherosclerotic (control) tissues. In cultures of human vascular smooth muscle cells grown from explants of internal mammary artery, expression of mRNA for transforming growth factor-beta 1 was significantly greater in subconfluent than in confluent smooth muscle cells (P = 0.05). Transforming growth factor type-beta III receptor was expressed in cell cultures and undetectable in the tissue specimens. Sections taken adjacent to those studied by in situ hybridization were examined by immunohistochemistry using antibodies against transforming growth factor-beta 1 and alpha-actin (as a marker for smooth muscle cells) and disclosed transforming growth factor-beta 1 in smooth muscle cells present in these sections. These findings are consistent with the concept that transforming growth factor-beta 1 plays an important role in modulating repair of vascular injury, including restenosis, after balloon angioplasty.

[1]  P. Serruys,et al.  Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet". , 1991, American heart journal.

[2]  A. Becker,et al.  Fibrocellular Tissue Response After Percutaneous Transluminal Coronary Angioplasty: An Immunocytochemical Analysis of the Cellular Composition , 1991, Circulation.

[3]  K. Karsch,et al.  Morphological Changes and Smooth Muscle Cell Proliferation After Experimental Excimer Laser Treatment , 1991, Circulation.

[4]  W. Casscells,et al.  Fibroblast and transforming growth factors in endothelial wound healing in vitro , 1991 .

[5]  R D Safian,et al.  Coronary atherectomy. Clinical, angiographic, and histological findings and observations regarding potential mechanisms. , 1990, Circulation.

[6]  M. Sporn,et al.  The Transforming Growth Factor‐Betas: Past, Present, and Future , 1990, Annals of the New York Academy of Sciences.

[7]  L. Madisen,et al.  Analysis of Proteolytic Cleavage of Recombinant TGF‐β1: Production of Hybrid Molecules with Increased Processing Efficiency , 1990, Annals of the New York Academy of Sciences.

[8]  T. Parker,et al.  Cardiac Myocytes as Targets for the Action of Peptide Growth Factors , 1990, Circulation.

[9]  J. C. Myers,et al.  Human nonmuscle myosin heavy chain mRNA: generation of diversity through alternative polyadenylylation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Sporn,et al.  Cloning by polymerase chain reaction of a new mouse TGF-beta, mTGF-beta 3. , 1990, Growth factors.

[11]  E. Chen,et al.  Complementary DNA Cloning of the Murine Transforming Growth Factor-β3 (TGFβ3) Precursor and the Comparative Expression of TGFβ3 and TGFβ1 Messenger RNA in Murine Embryos and Adult Tissues , 1989 .

[12]  O. Kocher,et al.  Endothelial cell behavior after denudation injury is modulated by transforming growth factor-beta1 and fibronectin. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[13]  M. Sporn,et al.  Expression of transforming growth factor-beta 1 in specific cells and tissues of adult and neonatal mice , 1989, The Journal of cell biology.

[14]  Julie H. Campbell,et al.  Arterial smooth muscle. A multifunctional mesenchymal cell. , 1988, Archives of pathology & laboratory medicine.

[15]  J. Murray,et al.  RFLP for the human transforming growth factor beta-1 gene (TGFB) on chromosome 19. , 1988, Nucleic acids research.

[16]  J. Davidson,et al.  The elastogenic effect of recombinant transforming growth factor-beta on porcine aortic smooth muscle cells. , 1988, Biochemical and biophysical research communications.

[17]  C. Heldin,et al.  INDUCTION OF B-TYPE RECEPTORS FOR PLATELET-DERIVED GROWTH FACTOR IN VASCULAR INFLAMMATION: POSSIBLE IMPLICATIONS FOR DEVELOPMENT OF VASCULAR PROLIFERATIVE LESIONS , 1988, The Lancet.

[18]  P. Cipriano,et al.  Transluminal atherectomy for occlusive peripheral vascular disease. , 1988, The American journal of cardiology.

[19]  E. Benditt.  Origins of human atherosclerotic plaques. The role of altered gene expression. , 1988, Archives of pathology & laboratory medicine.

[20]  R. Ross.  Growth factors in the pathogenesis of atherosclerosis. , 2009, Acta medica Scandinavica. Supplementum.

[21]  G. Bondjers,et al.  Endothelial dysfunction and injury in atherosclerosis. , 2009, Acta medica Scandinavica. Supplementum.

[22]  R. Majack.  Beta-type transforming growth factor specifies organizational behavior in vascular smooth muscle cell cultures , 1987, The Journal of cell biology.

[23]  R. Derynck,et al.  Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells , 1987, Cell.

[24]  J. Massagué.  The TGF-beta family of growth and differentiation factors. , 1987, Cell.

[25]  H. Ristow.  BSC-1 growth inhibitor/type beta transforming growth factor is a strong inhibitor of thymocyte proliferation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Baird,et al.  Inhibition of endothelial cell proliferation by type beta-transforming growth factor: interactions with acidic and basic fibroblast growth factors. , 1986, Biochemical and biophysical research communications.

[27]  M. Sporn,et al.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth , 1986, The Journal of experimental medicine.

[28]  N. Ratliff,et al.  Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. , 1985, Journal of the American College of Cardiology.

[29]  H. Moses,et al.  Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. , 1984, Science.

[30]  M. Sporn,et al.  Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C. B. Childs,et al.  Serum contains a platelet-derived transforming growth factor. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Sporn,et al.  New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Sporn,et al.  Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Todaro,et al.  Growth factors from murine sarcoma virus-transformed cells. , 1978, Proceedings of the National Academy of Sciences of the United States of America.